..\Images\People\Sharon.gif
  • Sharon Yeatts, MS, PhD
  • Senior Biostatistician
  • Professor of Biostatistics, Department of Public Health Sciences
  • College of Medicine, Medical University of South Carolina
  • Fax: 843-876-1923
  • Email: yeatts@musc.edu
  • Experience:
    Phase I-III clinical trials; Experimental design and statistical methods for assessing dose response
  • Research:
    Design, Conduct, and Analysis of Clinical Trials
  • Projects:
    Neurological Emergencies (ischemic stroke, intracerebral hemorrhage, traumatic brain injury)
Sharon Yeatts, PhD, is a Professor of Biostatistics in the Department of Public Health Sciences at the Medical University of South Carolina (MUSC). She received her MS in Statistics from the University of South Carolina (2002) and her PhD in Biostatistics from Virginia Commonwealth University (2006). As a faculty member in the Data Coordination Unit, Dr. Yeatts is involved in the design, conduct, and analysis of multicenter clinical trials in neurological disorders and emergency medicine. Dr. Yeatts is co-PI of the Data Coordinating Center for the SIREN (Strategies to Innovate Emergency Care Clinical Trials) network. She is PI of the DCC for several clinical trials conducted within the SIREN network: C3PO (Clinical Trial of COVID-19 Convalescent Plasma of Outpatients), ICECAP (Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients), and BOOST-3 (Brain Oxygen Optimization in Severe TBI Phase-3). Dr. Yeatts is also PI of the Data Management Center for SATURN (Statins in Intracerebral Hemorrhage), conducted within the StrokeNet network. Dr. Yeatts actively serves on grant review panels as well as DSMBs and is Statistical Editor of Stroke.

Publications
 
  • Frederick K. Korley, M.D., Ph.D., Valerie Durkalski-Mauldin, Ph.D., Sharon D. Yeatts, Ph.D., Kevin Schulman, M.D., Robertson D. Davenport, M.D., Larry J. Dumont, Ph.D., Nahed El Kassar, M.D., Ph.D., Lydia D. Foster, M.S., Jennifer M. Hah, M.D., Siddartha Jaiswal, M.D., Ph.D., Alesia Kaplan, M.D., Ezekiel Lowell, B.S., et al., for the SIREN-C3PO Investigators
  • Early Convalescent Plasma for High-Risk Outpatients with Covid-19
  • The New England Journal of Medicine
  • Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk A M, Bammer R, Lavori PW, Broderick JP, Lansberg MG on behalf of the DEFUSE 3 Investigators.
  • Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging.
  • New England Journal of Medicine. Accepted December 2017. Published January 24 2018.
  • Fan L, Yeatts SD, Foster LD, Khatri P, Tomsick T, Broderick JP, Palesch Y.
  • Endovascular Therapy Demonstrates Benefit Over IV rt-PA Based on Repeatedly Measured NIHSS.
  • Interventional Neurology. 2017; 6: 25-30.
  • Yeatts SD, Martin RH, Coffey CS, Lyden PD, Foster LD, Woolson RF, Broderick JP, DiTullio MR, Jungreis CA, Palesch YY for the IMS III Investigators.
  • The Challenges of Decision-Making Regarding Futility in a Randomized Trial: The IMS III Experience.
  • Stroke, 45: 1408-1414
  • Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators.
  • Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
  • N Engl J Med. 2013 Mar 7;368(10):893-903. doi: 10.1056/NEJMoa1214300. Epub 2013 Feb 7. Erratum in: N Engl J Med. 2013 Mar 28;368(13):1265.
  • Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, Schlaug G, Torbey M, Waldman B, Xi G, Palesch Y, on behalf of the DFO in ICH Investigators.
  • Safety and Tolerability of Deferoxamine Mesylate in Patients with Acute Cerebral Hemorrhage.
  • Stroke, 42: 3067-3074.
  • Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, Tomsick TA, for the IMS I and II Investigators.
  • Good Clinical Outcome After Ischemic Stroke with Successful Revascularization is Time-Dependent.
  • Neurology, 73(13): 1066-1072.

Presentations
 
  • Mu Y, Pavlov A, Yeatts SD, Saver JL, Khatri P.
  • Analyzing the modified Rankin Scale in Acute Stroke Clinical Trials.
  • Presented at the European Stroke Organization Conference, Barcelona. May 2016. Poster presentation.
  • Mu Y, Pavlov A, Yeatts SD, Khatri P.
  • Designing Stroke Clinical Trials with a Binary Endpoint: Determining the Appropriate Sample Size Inflation Factor for Non-adherence.
  • Presented at the European Stroke Organization Conference, Barcelona. May 2016. Poster presentation.
  • Fan L, Yeatts SD, Wolf BJ, McClure LA, Selim M, Palesch YY.
  • The Estimation of Misclassification via Continuous-time Hidden Markov Model.
  • Presented at the Eastern North American Region of the International Biometrics Society Spring Meeting, Austin TX. March 2016. Oral presentation.
  • Fan L, Yeatts SD, Wolf BJ, McClure LA, Selim M, Palesch YY.
  • The Impact of Covariate Misclassification using Generalized Linear Regression under Covariate-Adaptive Randomization.
  • Presented at the Eastern North American Region of the International Biometrics Society Spring Meeting, Miami FL. March 2015.
  • Kim J, Zhao W, Yeatts SD
  • Implementation of Advanced Randomization Algorithm with Integrated Study Drug Tracking
  • Society for Clinical Trials 36th Annual Meeting, May 2015, Arlington, VA, Oral presentation
  • Yeatts SD, Selim M, Palesch YY.
  • Futility Design Incorporating Concurrent Controls: A Variation on the Phase II Trial Design.
  • Presented at the Society for Clinical Trials, Boston, MA, 2013. Oral presentation.
  • Garofolo KM, Yeatts SD, Ramakrishnan V, Jauch EJ, Johnston KC, Durkalski VL.
  • Responder Analysis Outcomes in the Analysis of Acute Stroke Clinical Trials.
  • Presented at the Society for Clinical Trials, Boston, MA, 2013. Oral presentation.
  • Yeatts SD, Martin RH, Foster LD, Woolson RF, Broderick JP, Palesch YY.
  • The Challenges of Decision-Making Regarding Futility in a Randomized Trial: The IMS III Experience.
  • resented at the International Stroke Conference, Honolulu, HI, 2013. Oral presentation.
    *Among the top 10% of accepted abstracts and invited for presentation at Best of AHA Specialty Conferences at Scientific Sessions 2013 in Dallas, Texas.
  • Khatri P, Yeatts SD, Mazighi M, Broderick JPB, Liebeskind DS, Demchuk AM, Amarenco P, Foster LD, Goyal M, Hill MD, Palesch YY, Jauch EC, Haley EC, Tomsick TA.
  • Time to Angiographic Reperfusion is Highly Associated with Good Clinical Outcome in the Interventional Management of Stroke Phase III Trial.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Oral presentation.
  • Liebeskind DS, Tomsick TA, Yeatts S, Foster L, Carrozzella J, Jovin TG, Khatri P, Goyal M, Palesch Y, Broderick JPB.
  • Collaterals in the Interventional Management of Stroke (IMS) III Trial.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Poster presentation.
  • Nolte J, Gupta P, Davis M, Matheus M, Cianfoni A, Chaudry I, Yeatts S, Rumboldt Z, Turan T.
  • Association Between Low CBV and ICH in Acute Stroke Patients Undergoing Intra-Arterial Therapy.
  • Presented at the International Stroke Conference, Honolulu, HI, 2013. Poster presentation.
go to DPHS

go to MUSC